# Phase I, Open-Label, Dose-Escalation Study of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

> **NCT03538626** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 33 (actual)

## Conditions studied

- HIV Antibodies

## Interventions

- **BIOLOGICAL:** VRC-HIVMAB091-00-AB
- **BIOLOGICAL:** rHuPH20

## Key facts

- **NCT ID:** NCT03538626
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-21
- **Primary completion:** 2022-08-29
- **Final completion:** 2022-08-29
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2024-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03538626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03538626, "Phase I, Open-Label, Dose-Escalation Study of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03538626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*